PET imaging of tumor hypoxia using 18F-labeled pimonidazole

Acta Oncologica

Volumn 52, Issue 7, 2013, Pages 1300-1307

  Busk, Morten ^a   Jakobsen, Steen ^a   Horsman, Michael R ^a   Mortensen, Lise S ^a   Iversen, Ane B ^a   Overgaard, Jens ^a   Nordsmark, Marianne ^a   Ji, Xiaosheng ^b   Lee, David Y ^c   Raleigh, James R ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Hypoxyprobe Inc   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 O TOSYL 3 (2 NITROIMIDAZOLE 1 YL) PROPYL] PIPERIDINE; 18 F FLUOROAZOMYCIN ARABINOSIDE; 18 F PIMONIDAZOLE; FLUORODEOXYGLUCOSE F 18; PIMONIDAZOLE; TRACER; UNCLASSIFIED DRUG; PIMONIDAZOLE F 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; FLUORINATION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY; LIVER; MOUSE; NEOPLASM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; TREATMENT PLANNING; BREAST ADENOCARCINOMA; CELL HYPOXIA; FEMALE; HYPOXEMIA; PET SCANNER; TUMOR CELL LINE; TUMOR HYPOXIA;

ANIMALS; ANOXIA; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C3H; MICE, NUDE; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS; TUMOR CELLS, CULTURED;

EID: 84884564299     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.815797     Document Type: Article

References (29)

1. Vaupel P. Tumor microenvironmental physiology anDits implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206
2. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002;1:453-8
3. Overgaard J. Hypoxic radiosensitization: Adored anDignored. J Clin Oncol 2007;25:4066-74
4. Busk M, Horsman M R, Jakobsen S, Keiding S, Van Der Kogel AJ, Bussink J, et al. Imaging hypoxia in xenografted and murine tumors with 18 F-fluoroazomycin arabinoside: A comparative study involving microPET, autoradiography, PO2-polarography, and fl uorescence microscopy. Int J Radiat Oncol Biol Phys 2008;70:1202-12
5. Kaanders J H, Wijffels K I, Marres HA, Ljungkvist AS, Pop LA, Van Den Hoogen FJ, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-74
6. Busk M, Toustrup K, Sorensen BS, Alsner J, Horsman MR, Jakobsen S, et al. In vivo identifi cation and specifi city assessment of mRNA markers of hypoxia in human and mouse tumors. BMC Cancer 2011;11:63
7. Sorensen BS, Toustrup K, Horsman MR, Overgaard J, Alsner J. Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro. Acta Oncol 2010;49:895-905
8. Toustrup K, Sorensen B S, Nordsmark M, Busk M, Wiuf C, Alsner J, et al. Development of a hypoxia gene expression classifi er with predictive impact for hypoxic modifi cation of radiotherapy in head and neck cancer. Cancer Res 2011;71:5923-31
9. Toustrup K, Sorensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J. Gene expression classifi er predicts for hypoxic modifi cation of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012;102:122-9
10. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011;101:369-75
11. Toma-Dasu I, Uhrdin J, Antonovic L, Dasu A, Nuyts S, Dirix P, et al. Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncol 2012;51:222-30
12. Tran L B, Bol A, Labar D, Jordan B, Magat J, Mignion L, et al. Hypoxia imaging with the nitroimidazole 18 F-FAZA PET tracer: A comparison with OxyLite, EPR oximetry and 19 F-MRI relaxometry. Radiother Oncol 2012;105:29-35
13. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, et al. Exploratory prospective triaLof hypoxiaspecifi c PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012;105:21-8
14. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome . Nat Rev Clin Oncol 2012;9:674-87
15. Mortensen L S, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiother Oncol 2012;105:14-20
16. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-91
17. Abolmaali N, Haase R, Koch A, Zips D, Steinbach J, Baumann M, et al. Two or four hour [ 18 F]FMISO-PET in HNSCC. When is the contrast best? Nuklearmedizin 2011;50:22-7
18. Busk M, Horsman M R, Overgaard J. Resolution in PET hypoxia imaging: Voxel size matters. Acta Oncol 2008;47:1201-10
19. Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y. 18 F-HX4 hypoxia imaging with PET/CT in head and neck cancer: A comparison with 18 F-FMISO. Nucl Med Commun 2012;33:1096-102
20. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specifi c tumor imaging with 18 F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-13
21. Souvatzoglou M, Grosu AL, Roper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [ 18 F]FAZA PET in head and neck cancer patients: A pilot study. Eur J Nucl Med MoLimaging 2007;34:1566-75
22. Kleiter MM, Thrall DE, Malarkey DE, Ji X, Lee DY, Chou SC, et al. A comparison of oral anDintravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. Int J Radiat Oncol Biol Phys 2006;64:592-602
23. Busk M, Horsman MR, Jakobsen S, Bussink J, Van Der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med MoLimaging 2008;35:2294-303
24. Mortensen L S, Busk M, Nordsmark M, Jakobsen S, Theil J, Overgaard J, et al. Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: A preclinical study. Radiother Oncol 2011;99:418-23
25. Busk M, Munk OL, Jakobsen S, Wang T, Skals M, Steiniche T, et al. Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET. Acta Oncol 2010;49:922-33
26. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990;122:301-8
27. Dennis M F, Stratford M R, Wardman P, Watts M E. C ellular uptake of misonidazole and analogues witHacidic or basic functions. Int J Radiat Biol Relat Stud Phys Chem Med 1985;47:629-43
28. Oehler C, O 'Donoghue J A, Russell J, Zanzonico P, Lorenzen S, Ling CC, et al. 18 F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic aciDin colorectal xenograft tumors. J Nucl Med 2011;52:437-44
29. Reischl G, Dorow D S, Cullinane C, Katsifi s A, Roselt P, Binns D, et al. Imaging of tumor hypoxia with [ 124 I]IAZA in comparison with [ 18 F]FMISO and [ 18 F]FAZA-fi rst small animal PET results. J Pharm Pharm Sci 2007;10:203-11